| LIC | LMIC | UMIC | HIC | World | ||
|---|---|---|---|---|---|---|
| Vaccines | ||||||
| Secure Vaccines to Cover 70% of the Population | %. of Countries with Procurement Gap | 78 | 29 | 25 | 2 | 27 |
| Secure Vaccines to Cover 70% of the Population | Gap (Mn Doses) | 113 | 180 | 46 | 0 | 338 |
| Diagnostics | ||||||
| Test Over 1/1000 population per day | %. of Countries Not on Track | 100 | 73 | 63 | 59 | 56 |
| Test Over 1/1000 population per day | Gap (Mn Tests Daily) | 0.64 | 6.49 | 4.2 | 0.11 | 11.43 |
| Sequence > 1% of COVID Cases | %. of Countries Not on Track | 65 | 69 | 82 | 26 | 49 |
| Treatment / PPE | ||||||
| Oxygen Shortages | %. of Countries on Oxygen Crisis Risk List | 0 | 16 | 9 | 0 | 7 |
| Identified Funding Needs (% of Countries) | COVID-19 PCR Diagnostic Tests | 89 | 84 | 49 | 0 | 49 |
| Identified Funding Needs (% of Countries) | COVID-19 RDT Diagnostic Tests | 70 | 65 | 35 | 0 | 38 |
| Identified Funding Needs (% of Countries) | COVID-19 PPE | 81 | 82 | 53 | 0 | 49 |
| Identified Funding Needs (% of Countries) | COVID-19 Therapeutics - Oxygen | 89 | 78 | 45 | 0 | 47 |
| Identified Funding Needs (% of Countries) | COVID-19 Therapeutics - Other | 85 | 71 | 36 | 0 | 42 |
Last Update: 5 May 2022
The vaccination targets are to achieve at least 40% coverage in all countries by the end-2021 and 70% by mid-2022. Vaccines are the most effective tool to prevent severe disease and death, and lower transmission.
Sources: COVID-19 Vaccine Delivery Partnership Information Hub; WHO, UNICEF. Last Update: 5 May 2022. Country borders or names do not necessarily reflect the IMF’s official position.
Sources and Notes: COVAX, UNICEF, Africa CDC, IMF staff calculations. Committed doses are doses that the COVAX facility is required to procure. Support from e US has allowed COVAX to secure 1b Pfizer doses. These include a donation of 700m doses, and the rest 300m doses is treated as non-donations. However, for this presentation all 1b facilitated doses are included in the Pfizer category. The secured supply agreement numbers for SII-AstraZeneca and SII-Novavax are approximated based on COVAX Facility candidate-specific supply information. The dose donations are based on COVAX estimates based on commitments from donors to share doses bilaterally with the COVAX facility.
Last Update: 5 May 2022.